Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: Implications for the pathogenesis of EBV-associated B-cell lymphomas

Blood

Volumn 117, Issue 22, 2011, Pages 5907-5917

  Vrzalikova, Katerina ^a,b   Vockerodt, Martina ^a,c,d   Leonard, Sarah ^a   Bell, Andrew ^a   Wei, Wenbin ^a   Schrader, Alexandra ^c,d   Wright, Kenneth L ^e   Kube, Dieter ^c,d   Rowe, Martin ^a   Woodman, Ciaran B ^a   Murray, Paul G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d Deutsche Krebshilfe   (Germany)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1ALPHA; LATENT MEMBRANE PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GERMINAL CENTER; HUMAN; HUMAN CELL; ONCOGENE MYC; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; VIRUS REPLICATION;

EID: 79958002790     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307710     Document Type: Article

References (49)

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757-768. (Pubitemid 39331148)
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields Virology, 4th ed, vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2575-2627.
3. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol. 2001;66(1):122-131.
4. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987;6(9):2743-2751.
5. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields Virology, 4th ed, vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2511-2573.
6. Countryman J, Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A. 1985;82(12):4085-4089. (Pubitemid 15052833)
7. Takada K, Shimizu N, Sakuma S, Ono Y. Transactivation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol. 1986;57(3):1016-1022. (Pubitemid 16143985)
8. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood. 1995;85(3):744-750.
9. Crawford DH, Ando I. EB virus induction is associated with B-cell maturation. Immunology. 1986;59(3):405-409. (Pubitemid 16007091)
10. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol. 1997;182(2):151-159. (Pubitemid 27287835)
11. Niedobitek G, Agathanggelou A, Steven N, Young LS. Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol Pathol. 2000;53(1):37-42. (Pubitemid 30075073)
12. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005;79(2):1296-1307. (Pubitemid 40053911)
13. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity. 2003;19(4):607-620. (Pubitemid 37311441)
14. Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol. 2003;21:205-230. (Pubitemid 37174531)
15. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17(1):51-62. (Pubitemid 34874618)
16. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B-cell differentiation. Science. 1997;276(5312):596-599. (Pubitemid 27193684)
17. Lin KI, Lin Y, Calame K. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol. 2000;20(23):8684-8695. (Pubitemid 32245902)
18. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol. 2002;22(13):4771-4780. (Pubitemid 34620412)
19. Reljic R, Wagner SD, Peakman LJ, Fearon DT. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med. 2000; 192(12):1841-1848.
20. Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7(7):773-782. (Pubitemid 43905877)
21. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107(10):4090-4100. (Pubitemid 43726818)
22. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203(2):311-317. (Pubitemid 43290840)
23. Györy I, Fejér G, Ghosh N, Seto E, Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol. 2003;170(6):125-133.
24. Kelly G, Bell A, Rickinson AB. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med. 2002;8(10):1098-1104. (Pubitemid 35175964)
25. Kube D, Vockerodt M. Transient gene expression and MACS enrichment. In: Wilson J, ed. Epstein Barr Virus Protocols in Methods in Molecular Biology, vol. 174. Totowa, NJ: Humana; 2001:155-163.
26. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-3792.
27. Tam W, Gomez M, Nie K. Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas. Blood. 2008;111(4):2488- 2489. (Pubitemid 351451468)
28. Young LS, Lau R, Rowe M, et al. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol. 1991;65(6):2868-2874.
29. Hoffman GJ, Lazarowitz SG, Hayward SD. Monoclonal antibody against a 250 000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980;77(5):2979-2983. (Pubitemid 10049861)
30. Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205(10):2251-2268.
31. Vockerodt M, Morgan SL, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol. 2008;216(1):83-92.
32. Angelin-Duclos C, Cattoretti G, Lin K-I, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol. 2000;165(10):5462-5471.
33. Högerkorp CM, Borrebaeck CA. The human CD77- B cell population represents a heterogeneous subset of cells comprising centroblasts, centrocytes, and plasmablasts, prompting pheno-typical revision. J Immunol. 2006;177(7):4341-4349. (Pubitemid 44469762)
34. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol. 2005;79(2):1296-1307. (Pubitemid 40053911)
35. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A. 1973;70(1):190-194.
36. Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G. Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP-1 in vivo. J Virol. 2004;78(23):13253-13261. (Pubitemid 39507830)
37. Cahir-McFarland ED, Carter K, Rosenwald A, et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol. 2004;78(8):4108-4119.
38. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-1 mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol. 2000;1(6):526-532.
39. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133-169. (Pubitemid 351600373)
40. Anastasiadou E, Vaeth S, Cuomo L, et al. Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells. Cancer Lett. 2009;284(2):165-174.
41. Takada K, Ono Y. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol. 1989;63(1):445-449. (Pubitemid 19028127)
42. Sun CC, Thorley-Lawson DA. Plasma cell-specific transcription factor XBP-1 binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol. 2007;81(24):13566-13577. (Pubitemid 350247850)
43. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol. 2007;81(14):7363-7370. (Pubitemid 47047825)
44. Vallabhapurapu DS, Schimpl A, Berberich I. B Lymphocyte-induced maturation protein-1 (Blimp-1) is sufficient to trigger an unfolded protein response and XBP-1 processing in B cells. Signal Transduction. 2006;1:62-68. (Pubitemid 43374165)
45. Adler B, Schaadt E, Kempkes B, Zimber-Strobl U, Baier B, Bornkamm GW. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci U S A. 2002;99(1):437-442. (Pubitemid 34060379)
46. Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol. 2003;77(8):5000-5007. (Pubitemid 36402850)
47. Arpin C, Dechanet J, Van Kooten C, et al Generation of memory B cells and plasma cells in vitro. Science. 1995;268:720-722.
48. Randall TD, Heath AW, Santos-Argumedo L, Howard MC, Weissman IL, Lund FE. Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers. Immunity. 1998;8(6):733-742. (Pubitemid 28294520)
49. Knödel M, Kuss AW, Berberich I, Schimpl A. Blimp-1 over-expression abrogates IL-4- and CD40-mediated suppression of terminal B-cell differentiation but arrests isotype switching. Eur J Immunol. 2001;31(7):1972-1980. (Pubitemid 32640712)